Scholar Rock surges as genetic disease drug succeeds in late-stage trial

Biohaven

07/10/2024 16:26

(Updates)
    ** Shares of Scholar Rock  SRRK.O  more than quadruple in
value to $31.91
        ** Stock set to hit nearly 3-year high if gains hold    
  
    ** Says its drug, apitegromab, met the main goal in a
late-stage trial in patients with a type of rare genetic
neuromuscular disease
    ** Spinal muscular atrophy is a group of hereditary diseases
affecting motor neurons
    ** Shares of Biohaven  BHVN.N , which develops a rival drug
focusing on muscle retention, up 6.4% at $50.72 
    ** Including session gains, stock up 71.4% YTD

 (Reporting by Puyaan Singh and Mariam Sunny in Bengaluru)
 ((Puyaan.Singh@thomsonreuters.com;))